Literature DB >> 31291010

Intent and subsequent initiation of human papillomavirus vaccine among young cancer survivors.

Brooke Cherven1, Sharon M Castellino2, Yanjun Chen3, F Lennie Wong4, Jocelyn M York3, Karen Wasilewski-Masker2, Melissa M Hudson5, Smita Bhatia3, James L Klosky2,5, Wendy Landier1,3.   

Abstract

BACKGROUND: Despite an increased risk of subsequent human papillomavirus (HPV)-related malignancies, HPV vaccine initiation rates among cancer survivors remain critically low. The purpose of this study was to determine the relationship between HPV vaccine intent and subsequent vaccine initiation among cancer survivors by linking data from a cross-sectional survey with state-based immunization registry records.
METHODS: Cancer survivors who were 9 to 26 years old were surveyed 1 to 5 years after their treatment to assess their HPV vaccine initiation status, HPV vaccine intent, sociodemographic factors, and vaccine-related health beliefs. HPV vaccine doses/dates were abstracted from the Georgia Registry for Immunization Transactions for 3.5 years after survey participation. Logistic regression models identified factors associated with vaccine intent and subsequent vaccine initiation.
RESULTS: Among survivors who were HPV vaccine-naive at survey participation (n = 103), factors associated with vaccine intent included the following: 1) provider recommendation for the HPV vaccine (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.4-18.1; P = .014), 2) positive general attitude toward vaccines (OR, 4.8; 95% CI, 2.0-11.2; P < .001), and 3) perceived severity of HPV disease (OR, 3.5; 95% CI, 1.2-9.9; P = .02). Of the vaccine-naive patients, 28 initiated the HPV vaccine at a median of 1.1 years after the survey. Initiation was more likely among survivors who had reported vaccine intent (OR, 3.9; 95% CI, 1.2-12.5; P = .02) and was less likely among older survivors (OR per year, 0.7; 95% CI, 0.6-0.9; P < .001).
CONCLUSIONS: These findings suggest that provider recommendation for the HPV vaccine plays a role in establishing intent, which then translates into subsequent initiation.
© 2019 American Cancer Society.

Entities:  

Keywords:  adolescent; cancer survivors; papillomavirus vaccines; young adult

Mesh:

Substances:

Year:  2019        PMID: 31291010     DOI: 10.1002/cncr.32379

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Human papillomavirus vaccination uptake among childhood cancer survivors in Western New York.

Authors:  Melany Garcia; Cailey McGillicuddy; Elisa M Rodriguez; Kristopher Attwood; Jennifer Schweitzer; Scott Coley; Denise Rokitka; Nicolas F Schlecht
Journal:  Pediatr Blood Cancer       Date:  2022-09-12       Impact factor: 3.838

2.  Subsequent Primary Cancer Risk Among 5-Year Survivors of Adolescent and Young Adult Cancers.

Authors:  Hyuna Sung; Rebecca L Siegel; Noorie Hyun; Kimberly D Miller; K Robin Yabroff; Ahmedin Jemal
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

3.  Human papillomavirus (HPV) vaccination is cancer prevention for childhood cancer survivors.

Authors:  Heather M Brandt; Deanna Kepka; Anne C Kirchhoff; Casey L Daniel; Neel S Bhatt
Journal:  Cancer       Date:  2021-10-04       Impact factor: 6.860

4.  HPV vaccination coverage for pediatric, adolescent and young adult patients receiving care in a childhood cancer survivor program.

Authors:  Lauren Thomaier; Danielle A Aase; Rachel I Vogel; Helen M Parsons; Karim T Sadak; Deanna Teoh
Journal:  Prev Med Rep       Date:  2022-09-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.